Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Geologica Closes Financing And Property Acquisition (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Veracyte Inc VCYT

Healthcare Biotechnology
Veracyte, Inc. is a global diagnostics company. The Company enables clinicians with insights they need to guide and assure patients. The Company offers tests for thyroid cancer (Afirma), prostate cancer (Decipher Prostate), breast cancer (Prosigna), interstitial lung diseases (Envisia), and bladder cancer (Decipher Bladder). Its Percepta Nasal Swab test is being run in its Clinical Laboratory... see more

Recent & Breaking News (NDAQ:VCYT)

Veracyte Announces New Data Reinforcing Foundational Technology of Nasal Swab Test for Early Lung Cancer Detection Presented at CHEST Annual Meeting 2020

Business Wire October 19, 2020

Veracyte Announces Two Presentations to Be Shared at CHEST Annual Meeting 2020

Business Wire October 14, 2020

Veracyte to Release Third Quarter 2020 Financial Results on November 2, 2020

Business Wire October 7, 2020

Veracyte Receives ADLT Status for Envisia Genomic Classifier From Centers for Medicare and Medicaid Services

Business Wire September 24, 2020

Veracyte to Present at Two Investor Conferences

Business Wire September 15, 2020

Veracyte Announces Promotion of Richard T. Kloos, M.D. To Executive Medical Director

Business Wire September 14, 2020

Veracyte Announces Initiation of Consensus Study Exploring Medical Utility of Multiple Breast Cancer Genomic Tests

Business Wire September 11, 2020

Veracyte to Present at Upcoming Investor Conferences

Business Wire September 4, 2020

Veracyte Named a San Francisco Bay Area "Top Workplace" for Seventh Consecutive Year

Business Wire August 24, 2020

Veracyte Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters' Option to Purchase Additional Shares

Business Wire August 7, 2020

Veracyte Announces New Real-World Data Reinforcing the Potential Clinical Value of Percepta and Envisia Classifiers to Improve Diagnosis of Serious Lung Diseases

Business Wire August 5, 2020

Veracyte Announces Positive Clinical Utility Data for Percepta Classifier Published in CHEST

Business Wire August 5, 2020

Veracyte Announces Pricing of Public Offering of 6,000,000 Shares of Common Stock

Business Wire August 4, 2020

Veracyte Announces Proposed Public Offering of Common Stock

Business Wire August 3, 2020

Veracyte Announces Second Quarter 2020 Financial Results

Business Wire July 30, 2020

Veracyte Announces Data Published in AJRCCM Showing That the Envisia Genomic Classifier Improves Physicians' Ability to Diagnose IPF Without Surgery

Business Wire July 30, 2020

Veracyte and MAVIDx Announce Agreement for MAVIDx to Develop Ultra-High Volume COVID-19 Testing on the nCounter System

Business Wire July 29, 2020

Veracyte Appoints Jens Holstein to Board of Directors and James (Jim) Erlinger as Executive Vice President, General Counsel and Secretary

Business Wire July 27, 2020

Veracyte to Release Second Quarter 2020 Financial Results on July 30, 2020

Business Wire July 16, 2020

Veracyte Announces Clinical Utility Study Published in CHEST Demonstrates Envisia Genomic Classifier's Ability to Improve IPF Diagnosis

Business Wire June 11, 2020